|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||||||||
| Investments | |||||||||||||||||
| Control Investments | |||||||||||||||||
| Affiliate Investments | |||||||||||||||||
| Non-Control / Non-Affiliate Investments | |||||||||||||||||
| Total investments | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Restricted cash | |||||||||||||||||
| Interest receivable | |||||||||||||||||
| Deferred credit facility costs | |||||||||||||||||
| Other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| LIABILITIES | |||||||||||||||||
| Credit facility | |||||||||||||||||
| Secured Notes, net of $1,156 and $1,467, respectively, of unamortized deferred financing costs | |||||||||||||||||
| Notes | |||||||||||||||||
| 2025 Notes | |||||||||||||||||
| Series A Notes | |||||||||||||||||
| August 2026 Notes | |||||||||||||||||
| March 2029 Notes | |||||||||||||||||
| September 2029 Notes | |||||||||||||||||
| December 2026 Notes | |||||||||||||||||
| Convertible Notes, net of $605 and $1,243, respectively, of unamortized deferred financing costs and discount | |||||||||||||||||
| Unsecured Notes, net of $13,312 and $10,118, respectively, of unamortized deferred financing costs and premium/discount | |||||||||||||||||
| Distribution payable | |||||||||||||||||
| Security deposits | |||||||||||||||||
| Accounts payable, accrued expenses and other liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| NET ASSETS | |||||||||||||||||
| Common stock, $0.001 par value per share (200,000,000 authorized, 97,380,301 and 81,518,294 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively) | |||||||||||||||||
| Paid-in capital in excess of par | |||||||||||||||||
| Distributable earnings/(accumulated deficit) | |||||||||||||||||
| Total net assets | |||||||||||||||||
| Total liabilities and net assets | |||||||||||||||||
| NET ASSET VALUE PER SHARE | |||||||||||||||||
Loading...